Free Trial
NASDAQ:GRI

GRI Bio Q3 2023 Earnings Report

GRI Bio logo
$2.01 +0.10 (+5.24%)
As of 04:00 PM Eastern

GRI Bio EPS Results

Actual EPS
-$804.44
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GRI Bio Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

GRI Bio's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Friday, November 14, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

GRI Bio Earnings Headlines

Missed the Last 10,000% Surge? Here’s Your Next Chance
Wall Street’s already moving while most traders are still reacting — powered by data and AI tools the rest of us don’t see. That’s why we built Fierce Free Alerts: real-time signal notifications that cut through the noise and trigger the moment smart setups start forming.tc pixel
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

View GRI Bio Profile

More Earnings Resources from MarketBeat